Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
00 deaths 0.78 [0.28, 2.22]< 1 0% 5 studies (5/-) 67.7 % some concern not evaluable moderate crucial - clinical improvement 1.59 [1.21, 2.10]> 1 0% 4 studies (4/-) 100.0 % some concern not evaluable moderate important - clinical improvement (14-day) 1.26 [1.04, 1.53]> 1 0% 3 studies (3/-) 99.0 % some concern not evaluable moderate important - clinical improvement (28-day) 1.32 [0.86, 2.03]> 1 70% 2 studies (2/-) 89.4 % some concern not evaluable moderate important - clinical improvement (7-day) 1.50 [1.02, 2.21]> 1 0% 1 study (1/-) 97.9 % some concern not evaluable moderate important - clinical improvement (time to event analysis only) 1.67 [1.26, 2.23]> 1 0% 2 studies (2/-) 100.0 % some concern not evaluable moderate important - hospital discharge 1.41 [0.97, 2.03]> 1 0% 1 study (1/-) 96.6 % some concern not evaluable moderate important - PCR-negative conversion 1.75 [1.07, 2.87]> 1 63% 6 studies (6/-) 98.7 % some concern not evaluable moderate important - PCR-negative conversion (14-day) 1.12 [0.48, 2.63]> 1 32% 3 studies (3/-) 60.4 % some concern not evaluable moderate important - PCR-negative conversion (7-day) 1.44 [0.78, 2.65]> 1 61% 3 studies (3/-) 87.5 % some concern not evaluable moderate important - PCR-negative conversion (time to event analysis only) 1.32 [1.03, 1.69]> 1 0% 2 studies (2/-) 98.6 % some concern not evaluable moderate important - ventilation 0.06 [0.01, 0.83]< 1 0% 1 study (1/-) 98.2 % some concern not evaluable moderate important - ventilation (time to event analysis only) 0.06 [0.01, 0.83]< 1 0% 1 study (1/-) 98.2 % some concern not evaluable moderate important - ICU admission 1.21 [0.43, 3.39]< 1 0% 2 studies (2/-) 35.6 % some concern not evaluable moderate non important - 00 serious adverse events 2.71 [0.41, 18.02]< 1 0% 3 studies (3/-) 15.3 % some concern not evaluable moderate important - adverse events 2.16 [0.82, 5.68]< 1 80% 3 studies (3/-) 5.9 % some concern not evaluable moderate non important -
LoD: level of demonstration (
